Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients […]readmore
Tags : Respiratory
Shots: AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform The collaboration allows Gatehouse Bio to develop next-generation therapies […]readmore
Shots: The US FDA has granted orphan drug designation to Fasenra (benralizumab) for the treatment of eosinophilic esophagitis (EoE) following OD designation for EGPA in Nov’2018 and for hypereosinophilic syndrome […]readmore